| Type | Public |
| HQ | Mountain View, US |
| Founded | 1997 |
| Size (employees) | 66 (est)+7% |
| Website | chemocentryx.com |
ChemoCentryx was founded in 1997 and is headquartered in Mountain View, US
Report incorrect company information
Viewing summary data as a guest
Sign up for free to see all dataKey People/Management at ChemoCentryx
Thomas J. Schall
President, Chief Executive Officer and Chairman of the Board
Markus J. Cappel
Chief Business Officer and Treasurer
Report incorrect company information
ChemoCentryx Office Locations
ChemoCentryx has an office in Mountain View
Mountain View, (HQ)
850 Maude Avenue
Report incorrect company information
ChemoCentryx Financials and Metrics
ChemoCentryx Revenue
ChemoCentryx's revenue was reported to be $82.50 m in FY, 2017
| USD | |
|---|---|
Net income (Q3, 2018) | (10.9m) |
EBIT (Q3, 2018) | (11.5m) |
Market capitalization (4-Dec-2018) | 516.9m |
Closing stock price (4-Dec-2018) | 10.2 |
Cash (30-Sep-2018) | 24.1m |
EV | 507.5m |
ChemoCentryx's current market capitalization is $516.9 m.
Annual
Quarterly
| USD | Q3, 2013 | Q1, 2014 | Q2, 2014 | Q3, 2014 | Q1, 2015 | Q2, 2015 | Q3, 2015 | Q1, 2016 | Q2, 2016 | Q3, 2016 | Q1, 2017 | Q2, 2017 | Q3, 2017 | Q1, 2018 | Q2, 2018 | Q3, 2018 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
Revenue | 2.8m | 4.3m | 8.2m | 8.9m | 9.0m | 9.5m | ||||||||||
General and administrative expense | 2.9m | 3.5m | 3.4m | 3.5m | 3.7m | 3.6m | 3.8m | 4.1m | 3.9m | 3.2m | 4.6m | 4.2m | 3.6m | 4.7m | 4.7m | 5.4m |
R&D expense | 8.2m | 8.1m | 9.0m | 7.5m | 8.4m | 8.6m | 7.9m | 11.2m | 9.1m | 8.4m | 10.0m | 14.3m | 12.3m | 14.7m | 17.8m | 15.1m |
Operating expense total | 11.1m | 11.7m | 12.4m | 11.1m | 12.1m | 12.2m | 11.7m | 15.3m | 12.9m | 11.6m | 14.5m | 18.5m | 15.9m | 19.4m | 22.5m | 20.5m |
Annual
Quarterly
| USD | Q3, 2013 | Q1, 2014 | Q2, 2014 | Q3, 2014 | Q1, 2015 | Q2, 2015 | Q3, 2015 | Q1, 2016 | Q2, 2016 | Q3, 2016 | Q1, 2017 | Q2, 2017 | Q3, 2017 | Q1, 2018 | Q2, 2018 | Q3, 2018 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
Cash | 22.3m | 11.6m | 13.1m | 20.9m | 25.4m | 11.6m | 14.6m | 13.4m | 21.9m | 13.9m | 19.0m | 21.5m | 18.0m | 30.6m | 68.8m | 24.1m |
Accounts Receivable | 175.0k | 120.0k | 30.2m | 218.0k | 530.0k | 1.7m | 164.0k | 336.0k | ||||||||
Inventories | 1.3m | |||||||||||||||
Current Assets | 125.6m | 133.7m | 100.8m | 86.1m | 76.1m | 71.4m | 74.2m | 65.2m | 127.0m | 122.7m | 119.9m | 124.2m | 122.4m | 149.8m | 184.9m | 176.1m |
Annual
Quarterly
| USD | Q3, 2013 | Q1, 2014 | Q2, 2014 | Q3, 2014 | Q1, 2015 | Q2, 2015 | Q3, 2015 | Q1, 2016 | Q2, 2016 | Q3, 2016 | Q1, 2017 | Q2, 2017 | Q3, 2017 | Q1, 2018 | Q2, 2018 | Q3, 2018 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
Net Income | (29.1m) | (11.5m) | (12.3m) | (34.7m) | (12.0m) | (24.1m) | (11.6m) | (15.2m) | (25.2m) | (32.3m) | (6.0m) | (15.2m) | (21.8m) | (9.4m) | (16.3m) | (27.2m) |
Depreciation and Amortization | 426.0k | 153.0k | 414.0k | 259.0k | 86.0k | 173.0k | 260.0k | 203.0k | 311.0k | 111.0k | 227.0k | 371.0k | ||||
Inventories | 1.3m | |||||||||||||||
Accounts Payable | (58.0k) | (199.0k) | 690.0k | 121.0k | 809.0k | 280.0k | 615.0k | 619.0k | (162.0k) | 165.0k | 819.0k | 704.0k | 682.0k | (951.0k) | (378.0k) | (824.0k) |
| USD | Y, 2018 |
|---|---|
EV/EBIT | -44 x |
EV/CFO | 16 x |
Debt/Equity | 0.7 x |
Debt/Assets | 0.1 x |
Financial Leverage | 8.9 x |
Report incorrect company information
ChemoCentryx News and Updates
September 26, 2018
ChemoCentryx Announces Proposed Public Offering of Common Stock
MOUNTAIN VIEW, Calif., Sept. 26, 2018 (GLOBE NEWSWIRE) -- ChemoCentryx, Inc. (Nasdaq:CCXI) announced today that it has commenced an underwritten public offering of $75 million of its common stock. In connection with this offering, ChemoCentryx plans to grant the underwriters a 30-day option to pu…
March 23, 2018
ChemoCentryx: Significant Progress In Recent Months
Report incorrect company information
ChemoCentryx Blogs
September 28, 2018
ChemoCentryx Determines Not to Proceed with Public Offering of Common Stock
MOUNTAIN VIEW, Calif. , Sept. 27, 2018 (GLOBE NEWSWIRE) -- ChemoCentryx, Inc. (the "Company" or "ChemoCentryx") (Nasdaq:CCXI) announced today that it will not conclude an offering of shares of its common stock as announced on Wednesday, September 26, 2018 .
September 26, 2018
ChemoCentryx to Present at the Cantor Fitzgerald 2018 Global Healthcare Conference
MOUNTAIN VIEW, Calif. , Sept. 26, 2018 (GLOBE NEWSWIRE) -- ChemoCentryx, Inc. , (Nasdaq: CCXI), today announced that Thomas J. Schall , Ph.D., President and Chief Executive Officer, will present at the Cantor Fitzgerald 2018 Global Healthcare Conference on Tuesday October 2, 2018 at 1:40 p.m. ET .
ChemoCentryx Company Life and Culture
Report incorrect company information
ChemoCentryx Frequently Asked Questions
When was ChemoCentryx founded?
ChemoCentryx was founded in 1997.
Who are ChemoCentryx key executives?
ChemoCentryx's key executives are Thomas J. Schall and Markus J. Cappel.
How many employees does ChemoCentryx have?
ChemoCentryx has 66 employees.
What is ChemoCentryx revenue?
Latest ChemoCentryx annual revenue is $82.5 m.
What is ChemoCentryx revenue per employee?
Latest ChemoCentryx revenue per employee is $1.2 m.
Who are ChemoCentryx competitors?
Competitors of ChemoCentryx include Kiniksa Pharmaceuticals, Sartorius Stedim BioOutsource and Neurosearch.
Where is ChemoCentryx headquarters?
ChemoCentryx headquarters is located at 850 Maude Avenue, Mountain View.
Where are ChemoCentryx offices?
ChemoCentryx has an office in Mountain View.
How many offices does ChemoCentryx have?
ChemoCentryx has 1 office.